Evidence map›Paper›PMID 30926635›Full record

ArticleMolecular cancer therapeutics2019

BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells by Activating the Nur77-Bcl-2 Apoptotic Pathway.

Xiaohui Chen, Xihua Cao, Xuhuang Tu, Gulimiran Alitongbieke, Zebin Xia, Xiaotong Li, Ziwen Chen, Meimei Yin, Dan Xu, Shangjie Guo and 10 more

Open access · greenAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Exploring the nexus of nuclear receptors in hematological malignancies.Cellular and molecular life sciences : CMLS · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Reposition of the anti-inflammatory drug diacerein in anSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Xiaohui ChenSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Xihua Cao *Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Xuhuang TuSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Gulimiran AlitongbiekeSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Zebin XiaCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California.
Xiaotong LiSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Ziwen ChenSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Meimei Yin
Dan XuSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Shangjie GuoSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Zongxi LiSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Liqun Chen *School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Xindao ZhangSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Dingyu XuSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Meichun GaoSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Jie LiuSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Zhiping ZengSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Hu ZhouSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China.
Ying SuCancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California. ysu@sbpdiscovery.org xzhang@sbpdiscovery.org.
Xiao-Kun ZhangSchool of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen, China. ysu@sbpdiscovery.org xzhang@sbpdiscovery.org.
Xiamen University · CNDiscovery Institute · US

Funding

Nongenomic Coregulators of RXRalphaR01CA198982 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ZHANG, XIAO-KUN · 2018 to 2019
$879k
NCI NIH HHS R01 CA198982
6 · The paper itself

Abstract

Nur77 (also called TR3 or NGFI-B), an orphan member of the nuclear receptor superfamily, induces apoptosis by translocating to mitochondria where it interacts with Bcl-2 to convert Bcl-2 from an antiapoptotic to a pro-apoptotic molecule. Nur77 posttranslational modification such as phosphorylation has been shown to induce Nur77 translocation from the nucleus to mitochondria. However, small molecules that can bind directly to Nur77 to trigger its mitochondrial localization and Bcl-2 interaction remain to be explored. Here, we report our identification and characterization of DIM-C-pPhCF

Indexed as

AnimalsApoptosisGene Expression Regulation, NeoplasticHCT116 CellsHumansHydrocarbons, FluorinatedIndolesMCF-7 CellsMiceMitochondriaNeoplasmsNuclear Receptor Subfamily 4, Group A, Member 1Protein BindingProto-Oncogene Proteins c-bcl-2Signal TransductionXenograft Model Antitumor Assays1,1-bis(3'-indolyl)-1-(4-trifluoromethylphenyl)methaneBCL2 protein, humanBI1071Hydrocarbons, Fluorinatedindole-3-carbinolIndolesNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Proto-Oncogene Proteins c-bcl-2

Identifiers

PMID30926635
PMCPMC6527444
OpenAlexW2932310957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.